A multicenter, dose-finding study to evaluate the safety and efficacy of CNTY-101 in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy and diffuse cutaneous systemic sclerosis.
Now Recruiting
Learn more about Century’s current Phase 1 clinical trial, CALiPSO-1, with study ID number: NCT06255028 at clinicaltrials.gov.